Multiple Sclerosis Trial, Recruiting (NCT06267781)

Multiple Sclerosis Trial, Recruiting NCT06267781 Sponsor: IRCCS San Raffaele Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06267781 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older
You have agreed to take part and signed a consent form
You have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go) based on specific diagnostic guidelines from 2017
Your MS has been very active recently — meaning you have had at least 2 relapses, or 1 relapse plus signs of new disease activity seen on a brain scan, within the last 12 months
Your doctor has referred you to receive one of the following treatments as part of your normal care: a stem cell transplant (aHSCT), alemtuzumab, or ocrelizumab/ofatumumab, based on approved Italian and European medical guidelines

Who may not be able to join:

You have been diagnosed with a different form of MS — specifically primary progressive MS or secondary progressive MS (forms where the condition worsens more steadily rather than in relapses)
You have a known allergy or intolerance to any of the treatments used in the trial, or there is a medical reason why you cannot safely take them

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Massimo Filippi, IRCCS San Raffaele

Phone: +390226452846

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06267781

Sponsor: IRCCS San Raffaele

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +390226452846

More information: https://clinicaltrials.gov/study/NCT06267781

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older
You have agreed to take part and signed a consent form
You have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go) based on specific diagnostic guidelines from 2017
Your MS has been very active recently — meaning you have had at least 2 relapses, or 1 relapse plus signs of new disease activity seen on a brain scan, within the last 12 months
Your doctor has referred you to receive one of the following treatments as part of your normal care: a stem cell transplant (aHSCT), alemtuzumab, or ocrelizumab/ofatumumab, based on approved Italian and European medical guidelines

Who may not be able to join:

You have been diagnosed with a different form of MS — specifically primary progressive MS or secondary progressive MS (forms where the condition worsens more steadily rather than in relapses)
You have a known allergy or intolerance to any of the treatments used in the trial, or there is a medical reason why you cannot safely take them

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS San Raffaele

Registry

ClinicalTrials.gov

Start date

2 September 2022

Est. completion

2 September 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Number of fading/disappearing paramagnetic rim lesions (PRLs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov